We aimed at investigating the impact of the biological subtype of breast cancer on the risk of developing brain metastasis and the outcome of Egyptian patients with brain metastasis.
We retrospectively reviewed the clinical records of 2193 consecutive women (1947 with localized disease and 246 with metastatic disease at presentation) diagnosed with breast cancer between January 1999 and December 2010. We explored the relationship between the clinico-pathological factors (including the biological subtypes) and the incidence of brain metastasis, Brain metastasis free survival (BMFS), and the Brain metastasis specific survival (BMSS).
Median follow up period for the whole cohort was 43.5 months (IQR 26-74 months); 160 patients (7.3%) developed brain metastasis. Among the individual clinico-pathological parameters, larger tumors (p = 0.006), axillary LN positivity (p
Breast cancer biological subtype plays a pivotal role in predicting the pattern of failure of patients presenting with localized disease and the subsequent outcome after brain metastasis in addition to the classical prognostic factors.
Clinical trial identification
Legal entity responsible for the study
Cairo Oncology Center
All authors have declared no conflicts of interest.